


Thirty-day mortality rate for standard EVAR is lower compared with FEVAR (or open repair)

6,058 AAA patients unfit for open repair in VQI (2003-2022):
4.5% for open repair vs 1.4% for PSM matched EVAR, P < .001. (Khoury, J Vasc Surg, 2024)

Meta-analysis of 27 studies on 2974 patients with a short neck AAA or a complex AAA: 3.3% for FEVAR compared with 4.2% after open repair. (Jone, BJS Open 2019)


UK COMPASS: Perioperative mortality with FEVAR: 2.2% and off label EVAR 1.2%.





Early results from the pivotal trial substudy of the GORE EXCLUDER conformable endoprosthesis in <u>angulated</u> necks


- Overall technical success was achieved in 93/95 patients (97.9%).
- Primary effectiveness at 12 months (having device technical success and absence of type I and III endoleak, migration, sac enlargement or rupture, and conversion to open repair) was achieved in 94.8%.
- Four patients (4.3%) had a type IA endoleak, no intervention.
- No aneurysm-related deaths, ruptures, or migration through 12 months

Rhee et al, J Vasc Surg 2024, in press









Conclusions Recent – inside the IFU – innovations have accomplished a safe endovascular repair and mostly demonstrated excellent mid term effectiveness for AAAs with a "hostile" neck. These results challenge the concept of the hostile neck, which call for an individualized device selection approach, an already widespread practice across the globe. Long term (10 year) results are eagerly awaited.

